A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising.
The field of covalent biologics has made headway recently, as the only biotech in the space has bagged $100 million to move its pipeline to the clinic.
To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.